Navigation Links
Bayer Schering Exercises Option to Develop Solid Tumor BiTE Antibody with Micromet
Date:12/1/2009

dent for Business Development added: "Our research and preclinical development teams have done an excellent job in advancing the program since January of this year. Bayer Schering Pharma's early option exercise is a recognition of Micromet's development capabilities and confirms the promise of our BiTE antibody platform."

About BiTE Antibodies

BiTE® antibodies are designed to direct the body's cytotoxic, or cell-destroying, T cells against tumor cells, and represent a new therapeutic approach to cancer therapy. Typically, antibodies cannot engage T cells because T cells lack the appropriate receptors for binding antibodies. BiTE antibodies have been shown to bind T cells to tumor cells, ultimately inducing a self-destruction process in the tumor cells referred to as apoptosis, or programmed cell death. In the presence of BiTE antibodies, T cells have been demonstrated to serially eliminate tumor cells, which explains the activity of BiTE antibodies at very low concentrations. Through the killing process, T cells start to proliferate, which leads to an increased number of T cells at the site of attack.

About Micromet, Inc.

Micromet, Inc. is a biopharmaceutical company developing novel, proprietary antibodies for the treatment of cancer, inflammation and autoimmune diseases. Its product development pipeline includes novel antibodies generated with its proprietary BiTE® antibody platform, as well as conventional monoclonal antibodies. Two of Micromet's BiTE antibodies and three of its conventional antibodies are currently in clinical trials. Micromet's preclinical product pipeline includes several novel BiTE antibodies generated with its proprietary BiTE antibody platform technology. Micromet's collaboration partners include sanofi-aventis, Bayer Schering Pharma, Merck Serono, MedImmune and Nycomed.

Forward-Looking Statements

This release contains certain forward-looking
'/>"/>

SOURCE Micromet, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Simmons Firms Partner Trent Miracle Chosen to Help Lead National Litigation Against Bayer
2. Bayer HealthCare Pharmaceuticals Initiates Phase III Trial with Florbetaben PET Tracer for Imaging of Cerebral beta-Amyloid Plaques, a Pathological Hallmark of Alzheimers Disease
3. Bayer Consumer Care Launches Citracal(R) Calcium Plus Heart Health, First-Ever Leading Calcium Supplement to Help Support Bone AND Heart Health
4. Bayer HealthCare Presents Florbetaben Phase II Study Results at World Congress of Neurology
5. Bayer and Onyx Announce Nexavar Data Presentations at 60th American Association for the Study of Liver Diseases Annual Meeting
6. Bayers Novel Anti-Cancer Compound Regorafenib (BAY 73-4506) Showed Stabilization or Regression in 81 Percent of Kidney Cancer Patients
7. Bayer Announces New Data on Oncology Portfolio To Be Presented at the ECCO-ESMO Congress 2009
8. Enrollment Completed in Regeneron and Bayer HealthCare Phase 3 Studies of VEGF Trap-Eye in Neovascular Age-Related Macular Degeneration (Wet AMD)
9. Bayer Announces New Data on Novel Anti-cancer Compound BAY 73-4506
10. Bayer Announces Leukine(R) Data Presentations at 45th American Society of Clinical Oncology (ASCO) Annual Meeting
11. Bayer and Regeneron Extend Development Program for VEGF Trap-Eye to Include Central Retinal Vein Occlusion
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/3/2015)... 3, 2015  Array BioPharma Inc. (NASDAQ: ... quarter and full year of its fiscal year ... Chief Executive Officer of Array, noted, "Binimetinib and encorafenib, ... on track for regulatory submissions in 2016. Additional ... and BRAF-mutant colorectal cancer further validate the value ...
(Date:8/3/2015)... Aug. 3, 2015  Charleston Laboratories, Inc., an ... second clinical development program with a Phase 1 ... CL-H1T contains fast-dissolving promethazine and sumatriptan.  ... a treatment for migraine headache pain and migraine-induced ... patients with migraine headaches also suffer from nausea ...
(Date:8/3/2015)... FLORHAM PARK, N.J. , Aug. 3, ... met its primary and secondary endpoints in a phase ... constipation (OIC) in adult patients with chronic non-cancer pain. ... antagonist (PAMORA). This is the third Phase III trial ... endpoints. Study results showed that a 0.2 ...
Breaking Medicine Technology:Array BioPharma Reports Financial Results For The Fourth Quarter And Full Year Of Fiscal 2015 2Array BioPharma Reports Financial Results For The Fourth Quarter And Full Year Of Fiscal 2015 3Array BioPharma Reports Financial Results For The Fourth Quarter And Full Year Of Fiscal 2015 4Array BioPharma Reports Financial Results For The Fourth Quarter And Full Year Of Fiscal 2015 5Array BioPharma Reports Financial Results For The Fourth Quarter And Full Year Of Fiscal 2015 6Array BioPharma Reports Financial Results For The Fourth Quarter And Full Year Of Fiscal 2015 7Array BioPharma Reports Financial Results For The Fourth Quarter And Full Year Of Fiscal 2015 8Array BioPharma Reports Financial Results For The Fourth Quarter And Full Year Of Fiscal 2015 9Array BioPharma Reports Financial Results For The Fourth Quarter And Full Year Of Fiscal 2015 10Array BioPharma Reports Financial Results For The Fourth Quarter And Full Year Of Fiscal 2015 11Array BioPharma Reports Financial Results For The Fourth Quarter And Full Year Of Fiscal 2015 12Charleston Laboratories, Inc. Initiates Patient Enrollment in a Phase 1 Study of Charleston's Second Product, CL-H1T 2Naldemedine Meets Primary Endpoint In Phase 3 Study For The Treatment Of Opioid-Induced Constipation 2Naldemedine Meets Primary Endpoint In Phase 3 Study For The Treatment Of Opioid-Induced Constipation 3Naldemedine Meets Primary Endpoint In Phase 3 Study For The Treatment Of Opioid-Induced Constipation 4
... /PRNewswire-Asia/ -- Simcere Pharmaceutical Group (NYSE: SCR ... specializing in the development, manufacturing, and marketing of branded ... annual general meeting of shareholders (the "Meeting") will be ... Beijing time. The meeting will be held at No.699-18, ...
... /PRNewswire-iReach/ -- Global Information Inc. is pleased to ... Therapy market: Global Protein Therapeutics Market ... become one of the most effective clinical methods to ... metabolic disorders. While worldwide healthcare spending has decline in the ...
Cached Medicine Technology:Simcere Pharmaceutical Group Provides Notice of Annual General Meeting 2New Forecast Shows Global Protein Therapeutics Market to Reach $143.4 Billion by 2015 2
(Date:8/3/2015)... ... August 03, 2015 , ... ... contract research organisations (CROs) for a slew of benefits, allowing them to gain ... operations, boost quality with cost-effective utilisation of resources, get access to innovation and ...
(Date:8/3/2015)... ... August 03, 2015 , ... Dental practice in Los Angeles ... need. Most people know that general health emergencies, such as broken arms or a ... people know where to turn to during a dental emergency. This is important, because ...
(Date:8/3/2015)... ... August 03, 2015 , ... AxoGen, Inc. (NASDAQ: AXGN), a leader ... present at the Wedbush Healthcare Conference on Wednesday, August 12, 2015 at 9:45am (ET) ... archived replay of the Company’s presentation may be accessed via the investor relations section ...
(Date:8/3/2015)... (PRWEB) , ... August 03, 2015 , ... A July ... Injection of Stem Cells Found to Release Natural Painkiller That Can Last 'For Five ... patients. According to the report, the new study showed that harvesting stem cell-rich bone ...
(Date:8/3/2015)... ... August 03, 2015 , ... Constantin Vasilica, 48 from Romania wanted to ... by diabetes after many years of suffering and using medications with strong side effects. ... to ask for extra time off or wait longer hours in the waiting rooms. ...
Breaking Medicine News(10 mins):Health News:Global CRO Market Space Reviewed by Aniruddha Sowale in In-demand Research Report Available at MarketPublishers.com 2Health News:Global CRO Market Space Reviewed by Aniruddha Sowale in In-demand Research Report Available at MarketPublishers.com 3Health News:Los Angeles Dental Practice, Sunset Plaza Dental, Now Offers Emergency Dental Services 2Health News:Los Angeles Dental Practice, Sunset Plaza Dental, Now Offers Emergency Dental Services 3Health News:AxoGen, Inc. to Present at the Wedbush Healthcare Conference 2Health News:Los Angeles Spine Surgeon Gives Insight into How Stem Cells Can Relieve Back Pain 2Health News:Los Angeles Spine Surgeon Gives Insight into How Stem Cells Can Relieve Back Pain 3Health News:Chinese Health Care Provider Heshoutang Now Give Patients Complimentary Online Healing Options 2Health News:Chinese Health Care Provider Heshoutang Now Give Patients Complimentary Online Healing Options 3
... Introduces New Educational ... Resource at IDSA Annual Meeting, HADDON HEIGHTS, ... a new continuing education,resource as part of their exhibit booth ... America (IDSA), October 4-7, in San Diego,California. Project CDAD: Outbreak ...
... reveal new ways of controlling and treating breast cancer ... today (Monday 1 October 2007). , Dr Robert Clarke ... group have been investigating human breast cancers for the ... tumours and can cause the cancer to recur - ...
... CHICAGO, Oct. 1 Y-ME Illinois will host a ... and,friends. The BIG Night Out - Indulgence for ... 6:30 p.m. to 10:00 p.m. in the Great Hall ... pamper themselves by,partaking in indulgences such as onsite spa ...
... Oct. 1 /PRNewswire-FirstCall/ - NUCRYST Pharmaceuticals,Corp. today ... signed amended,agreements with Smith & Nephew wound ... dressings with SILCRYST(TM) nanocrystalline coatings.,The two companies ... when Smith &,Nephew bought the Acticoat(TM) brand ...
... WINDSOR, Conn., Oct. 1 UTC Power, a,United ... announced it has,acquired Dome- Tech Group, a national ... New York City. Financial terms were not disclosed. ... energy costs,and improve overall efficiency. It facilitates green, ...
... Achieve Optimum Health, SOMERSET, N.J., Oct. 1 ... announced that it has launched a fourth business,segment, ... pharmaceutical,companies and healthcare payors achieve the best possible ... and stay on the right therapy, everyone wins ...
Cached Medicine News:Health News:National Experts Team Up to Help Hospitals Prevent and Control C. difficile Outbreaks 2Health News:Manchester researchers announce new methods of beating breast cancer 2Health News:Y-ME Illinois Hosts the First-Ever 'BIG Night Out' - Indulgence for a Cause 2Health News:NUCRYST and Smith & Nephew Revise Agreements 2Health News:NUCRYST and Smith & Nephew Revise Agreements 3Health News:NUCRYST and Smith & Nephew Revise Agreements 4Health News:NUCRYST and Smith & Nephew Revise Agreements 5Health News:NUCRYST and Smith & Nephew Revise Agreements 6Health News:NUCRYST and Smith & Nephew Revise Agreements 7Health News:UTC Power Acquires Dome-Tech Group 2Health News:inVentiv Health Launches Fourth Business Segment: inVentiv Patient Outcomes 2Health News:inVentiv Health Launches Fourth Business Segment: inVentiv Patient Outcomes 3
... a powerful, compact and programmable 8-channel ... dispensing pumps. Dispense and aspirate head ... horizontal needle positioning in the well. ... waste bottles and vacuum sensing allow ...
... is a solid made, manual plate ... valves for dispense and aspirate function ... complete with a stand and all ... be used, as well as any ...
... of microplate washers are precise, fast and ... manifold, providing independent control of both dispense ... and overflow protection in both 96- and ... the most precise and reliable washer available ...
... The Microplate washer MP-1200 is ... microplate washing system. Its internal micropumps ... and to discharge from all types ... microplate to be washed in rows ...
Medicine Products: